ArticleTranslational lung cancer research2025
Uniportal video-assisted thoracoscopic surgery does not increase recurrence rates following pneumonectomy in non-small cell lung cancer: a retrospective study from the National Cancer Center of China.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of perioperative hospital stay, postoperative chest tube retention, pain levels between uniportal and multiportal thoracoscopic lung cancer resection patients.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The safety, feasibility, and potential benefits of uniportal video-assisted thoracoscopic surgery (U-VATS) pneumonectomy remain to be investigated. This study aimed to evaluate the postoperative outcomes, survival prognosis, and recurrence patterns in patients undergoing U-VATS versus those undergoing open pneumonectomy. The feasibility of U-VATS pneumonectomy in patients receiving neoadjuvant systemic therapy was also assessed. Methods: Patients with non-small cell lung cancer (NSCLC) underwent thoracic surgeries at the Cancer Hospital, Chinese Academy of Medical Sciences (CHCAMS) from January 2017 to December 2022. Among these patients, those who underwent U-VATS or open pneumonectomy were included in our study. Propensity score matching (PSM) with a 3:1 ratio was conducted to balance the baseline characteristics between the groups. We compared perioperative outcomes and recurrence patterns between the two groups. Results: A total of 457 patients who underwent pneumonectomy were included in our study, with 348 in the open pneumonectomy group and 109 in the U-VATS group. After PSM, 334 patients (231 in the open group and 103 in the U-VATS group) were available for subsequent analyses. Patients who underwent U-VATS pneumonectomy experienced shorter postoperative hospital stays (P<0.001). No significant differences were observed in the 5-year overall survival (OS) rate (P=0.19) or the 5-year recurrence-free survival (RFS) rate (P=0.37) between the two groups. Additionally, subgroup analysis of patients receiving neoadjuvant systemic therapy indicated those in the U-VATS group did not exhibit significant differences in recurrence patterns between the two groups. Conclusions: Patients with NSCLC undergoing U-VATS pneumonectomy exhibit postoperative outcomes, survival rates, and recurrence patterns that are not inferior to those of patients undergoing open pneumonectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.